Читать книгу Genome Editing in Drug Discovery - Группа авторов - Страница 3

1 Chapter 4Table 4.1 Major providers of CRISPR reagents.Table 4.2 Genome editing service providers.

2 Chapter 5Table 5.1 Type of CRISPRs and properties.Table 5.2 Web‐based tools for target design with potential off‐target sites...Table 5.3 Editing activity prediction tools.Table 5.4 Editing outcome prediction tools.Table 5.5 Web tools for analysis.

3 Chapter 6Table 6.1 Variety of in vitro systems available for cellular disease modeli...

4 Chapter 7Table 7.1 Comparison of Cas9 proteins.

5 Chapter 8Table 8.1 Some of the available academic and commercial human and mouse poo...

6 Chapter 9Table 9.1 CRISPR reagent delivery methods. General advantages and limitatio...

7 Chapter 11Table 11.1 Arrayed versus pooled CRISPR screens.

8 Chapter 12Table 12.1 Summary of pooled genetic screens that combine CRISPR perturbati...Table 12.2 Epigenomic technologies that have been developed for single‐cell...

9 Chapter 13Table 13.1 Phase I and II clinical trials with applied designer nucleases a...Table 13.2 Phase I and II clinical trials with designer nucleases in immuno...

10 Chapter 15Table 15.1 A summary of the RNA editing technologies developed so far.

11 Chapter 16Table 16.1 A decade of gene‐targeting experiments in primary T cells.Table 16.2 Knock‐out experiments performed on primary T cells.

12 Chapter 17Table 17.1 List of clinical trials for various human diseases using genome‐...

13 Chapter 18Table 18.1 Overview of viral vectors used for gene therapy.

14 Chapter 20Table 20.1 Summary of in silico off‐target detection tools.Table 20.2 Summary of genome‐wide methods for detecting CRISPR‐Cas9 off‐tar...